Staidson BioPharm(SZ:300204)2022-12-07 08:54Group 1: Sales and Market Position - Su Tai Shen's Su Tai Sheng sales volume in 2014 was 4,577,919 bottles [3] - Su Tai Sheng holds the largest market share among four domestic varieties of mouse nerve growth factor [4] Group 2: Product Development and Differentiation - The human nerve growth factor developed by the company is an upgraded product of mouse nerve growth factor, utilizing recombinant gene technology [5] - The human nerve growth factor has advantages in homology compared to mouse nerve growth factor [5] Group 3: International Expansion and Strategy - The U.S. subsidiary has established its work direction, completed site leasing and renovation, and initiated personnel recruitment [5] - The Hong Kong subsidiary aims to leverage the favorable business environment for international investment and financing activities in the biopharmaceutical field [6] Group 4: Product Safety and Efficacy - Mouse nerve growth factor is currently the clearest product for direct repair of nerve damage, with fewer adverse reactions and high safety, stability, and effectiveness [6] - Su Tai Qing is safe and effective for use by elderly individuals, pregnant women, and children [6] Group 5: Research and Development Investment - R&D investment is closely related to the progress and stages of R&D projects, with the company emphasizing innovative research without compromising investment due to external factors [6]